Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
Adial Pharmaceuticals has announced the issuance of patent number 12,226,401, which enhances their genetic-based approach for treating alcohol and opioid use disorders. This new patent focuses on ...
LOS ANGELES, CA - February 13, 2026 - PRESSADVANTAGE - Muse Treatment Alcohol & Drug Rehab Los Angeles has released ...
The first published evidence from humans that semaglutide specifically reduces the symptoms of alcohol use disorder (AUD) has been published in The Journal of Clinical Psychiatry and details a recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results